| 1 |
Boyle JJ, Pfail JL, Lichtbroun BJ, Singer EA. Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments. JCO Precis Oncol 2023;7:e2200407. [PMID: 36724413 DOI: 10.1200/PO.22.00407] [Reference Citation Analysis]
|
| 2 |
Poplawski P, Alseekh S, Jankowska U, Skupien-Rabian B, Iwanicka-Nowicka R, Kossowska H, Fogtman A, Rybicka B, Bogusławska J, Adamiok-Ostrowska A, Hanusek K, Hanusek J, Koblowska M, Fernie AR, Piekiełko-Witkowska A. Coordinated reprogramming of renal cancer transcriptome, metabolome and secretome associates with immune tumor infiltration. Cancer Cell Int 2023;23:2. [PMID: 36604669 DOI: 10.1186/s12935-022-02845-y] [Reference Citation Analysis]
|
| 3 |
Aalami AH, Abdeahad H, Aalami F, Amirabadi A. Can microRNAs be utilized as tumor markers for recurrence following nephrectomy in renal cell carcinoma patients? A meta-analysis provides the answer. Urol Oncol 2023;41:52.e1-52.e10. [PMID: 36280530 DOI: 10.1016/j.urolonc.2022.09.022] [Reference Citation Analysis]
|
| 4 |
Lee HW, Seo HS, Yeom S, Kim S, Kim CR, Park D, Park W, Choy YB, Park CG, Seo SI. Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. IJMS 2022;23:12634. [DOI: 10.3390/ijms232012634] [Reference Citation Analysis]
|
| 5 |
Manini C, López JI. Updating Clear Cell Renal Cell Carcinoma (a Tribute to Prof. Ondrej Hes). Cancers 2022;14:3990. [DOI: 10.3390/cancers14163990] [Reference Citation Analysis]
|
| 6 |
Bin Riaz I, Riaz Sipra QUA, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH. Quantifying Absolute Benefit for Adjuvant Treatment Options in Renal Cell Carcinoma: A Living Interactive Systematic Review and Network Meta-analysis. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
